Growth Factor Coated Sutures for Improved Tendons Repair

描述(由申请人提供)：肌腱损伤相当常见，随着人口老龄化，这些损伤的频率预计会上升，但仍将继续活跃。因为肌腱愈合是一个相对缓慢的过程，所以需要长时间的制动和康复。通过提高治愈率和增加修复组织的强度来缩短这一时间段的创新将对患者和社会具有重大价值。早期活动被认为有助于更好地恢复功能，加速愈合，并提高肌腱修复组织的质量。然而，这种早期的运动和活动不能以增加两个肌腱末端的裂隙或甚至坦率地再次断裂为代价。已经尝试使用超声波、机械刺激和生长因子来提高愈合率，以提供足够的机械强度，使患者能够开始活动，将负荷施加到愈合的肌腱上，同时仍然保护初始缝合修复的完整性。这项第一阶段SBIR建议的目标是验证IFBM方法，将生长因子等生物活性分子结合到不可吸收的聚酯缝合线(Ethiond，ethcon，Inc.)上，这种缝合线通常用于许多类型的肌腱修复。我们提出了一种新的方法来创建与生物活性物质(生长因子、细胞等)结合的靶标特异性模块化多肽。到合成的生物相容表面(基质聚合物、金属等)。这些特定的和接枝的生物聚合物被称为“界面生物材料”(IFBMs)。双功能IFBM具有独特的优点：a)提供必要的表面结合专一性，b)包括广泛应用的强健化学，以及c)提供在单一支架或表面上指定广泛的相关或独立的生物活性的能力。软骨衍生形态发生蛋白(CDMP)-1、-2和-3(也称为BMP-14、-13和-12)最近被证明与肌腱的发育和愈合有关。我们相信，结合生长因子，如CDMP家族的那些，用IFBM技术缝合可以通过增加愈合率和改善修复组织的质量来显著改善手术修复肌腱的临床结果。

DESCRIPTION (provided by applicant): Tendon injuries are quite common and the frequency of these injuries is expected to rise as the population ages, yet continues to remain active. Long periods of immobilization and rehabilitation are required because tendon healing is a relatively slow process. Innovations that can shorten this time period by improving healing rates and increasing the strength of repair tissue will be of great value for patients and society. Earlier activity is believed to promote better return of function, accelerated healing, and improved quality of tendon repair tissue. However, this early motion and activity cannot be at the cost of increasing gapping of the two tendon ends or even frank re-rupture. Attempts have been made with ultrasound, mechanical stimulation, and growth factors to increase healing rates to provide enough mechanical strength to allow patients to start activity that will put load on the healing tendons, while still protecting the integrity of the initial suture repair. The goal of this Phase I SBIR proposal is to validate an IFBM approach to bind bioactive molecules such as growth factors to non-absorbable polyester suture (Ethibond, Ethicon, Inc.), which is commonly used in many types of tendon repair. We present a novel approach to create target-specific modular peptides that bind bioactive agents (growth factors, cells, etc.) to synthetic biocompatible surfaces (matrix polymer, metal, etc.). These specifying and grafting biopolymers are termed "interfacial biomaterials" (IFBMs). A bi-functional IFBM has the unique advantages of a) providing requisite surface binding specificity, b) comprising robust chemistry for broad-based applications and c) offering capacity to specify a wide range of associated or independent biological activities onto a single scaffold or surface. Cartilage derived morphogenetic proteins (CDMP) -1, -2 and -3 (also known as BMP -14, -13, and -12) have recently been shown to be involved in tendon development and healing. We believe that binding growth factors such as those of the CDMP family to suture with IFBM technology could significantly improve the clinical outcomes after surgical repair of tendons by increasing healing rates and by improving the quality of the repair tissue.